NCT05032807View on ClinicalTrials.gov

Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

August 26, 2022

Study Completion Date

September 10, 2022

Conditions
Absorption; Chemicals
Interventions
DRUG

Standard formulation

Cannabidiol 1000mg standard formulation, single dose, oral

DRUG

Novel formulation

Cannabidiol 1000mg with lipid matrix, single dose, oral

Trial Locations (1)

SE5 8AB

King's College London, London

All Listed Sponsors
lead

King's College London

OTHER